PharmaResearch

PharmaResearch is a biotechnology pharmaceutical company specializing in regenerative medicine. The company's core patented technology is "DOT," which stands for DNA Optimizing Technology. This technology involves extracting DNA from salmon reproductive cells and optimizing it into regenerative substances. In 2026, PharmaResearch's new generation of nanoscale anti-cancer drug, PRD-101, received FDA approval for its Investigational New Drug (IND) application, and the company will initiate Phase I clinical trials. PRD-101 is the first anti-cancer formulation developed using the company's patented "DOT" technology to create nucleic acids.